retatrutide new zealand (LY3437943) | GCGR/GLP-1R/GIPR Agonist | CAS 2381089-83-2 Beyond the GLP-1RA weight loss

These are not direct pharmacological effects of the medication

According to a study by Boston Universitys School of Public Health, 75% of employers cover GLP-1s for diabetes, but only 25% for weight loss

The country's well-developed private healthcare sector demonstrates strong uptake of obesity pharmacotherapy among patients willing to bear treatment costs

How effective is Retatrutide for non-diabetic weight loss

Factors that influence optimal maintenance dose include starting body composition, individual metabolic response, side effect tolerance, and research goals

It's also possible that GLP- 1 affects cells indirectly